Handbook of Clinical medicine

myelitis, meningitis, 427 uveitis, vision/hearing impairment, social isolation, psychological eff ects. Diagnosis: PPE (see BOX ‘Equipment’) if high possibility (see ‘Risk assessment’). WCC, plt, AST>ALT. IgM (~day 3), IgG (~day 7), reverse transcriptase PCR on blood/urine/saliva/ throat swab. Exclude malaria. Treatment: Supportive: fl uid resuscitation, correct electrolytes/coagulation/glu- Equipment cose, treat secondary infection, nutrition. Ribavirin not • Double gloves eff ective. Trace contacts, support family. Experimental: • Fluid-repellent gown anti-RNA agents, immunotherapy with blood/plasma • Full-length plastic apron from survivors, monoclonal antibodies (ZMapp™), • Head cover (surgical cap) Ebola vaccine (rVSV-ZEBOV, Ebola ça suffit! trial). Ethics: • Fluid-repellent footwear Randomization versus compassionate use: is it ethi- • Full face shield cal to withhold even potentially benefi cial therapy to • Full-repellent respirator a control group with a life-threatening condition? Is • Meticulous removal. observational data gained through the compassionate use of experimental therapy suffi cient to guide clinical decisions? Where should re- sources be directed to improve outcome: drug development or basic healthcare provi- sion, eg would the capacity to check K+ improve mortality? Marburg, Lassa, and CCHF Diff erentiating features are given in table 9.23. Table 9.23 Diff erentiation between VHF VHF Clinical features Marburg Incubation typically 5–9d. Clinically identical
